Journey Medical (DERM) Competitors $6.18 -0.03 (-0.48%) Closing price 04:00 PM EasternExtended Trading$6.22 +0.04 (+0.58%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DERM vs. REPL, ABUS, VECT, KALV, AVBP, TRVI, RCKT, PHAR, ANAB, and LENZShould you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Replimune Group (REPL), Arbutus Biopharma (ABUS), VectivBio (VECT), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Rocket Pharmaceuticals (RCKT), Pharming Group (PHAR), AnaptysBio (ANAB), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Journey Medical vs. Replimune Group Arbutus Biopharma VectivBio KalVista Pharmaceuticals ArriVent BioPharma Trevi Therapeutics Rocket Pharmaceuticals Pharming Group AnaptysBio LENZ Therapeutics Replimune Group (NASDAQ:REPL) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking. Which has preferable valuation & earnings, REPL or DERM? Journey Medical has higher revenue and earnings than Replimune Group. Journey Medical is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.07-2.51Journey Medical$56.13M2.54-$3.85M-$0.74-8.35 Do analysts rate REPL or DERM? Replimune Group presently has a consensus price target of $19.43, suggesting a potential upside of 151.99%. Journey Medical has a consensus price target of $9.88, suggesting a potential upside of 59.79%. Given Replimune Group's higher probable upside, research analysts plainly believe Replimune Group is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Journey Medical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk & volatility, REPL or DERM? Replimune Group has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Does the MarketBeat Community favor REPL or DERM? Replimune Group received 163 more outperform votes than Journey Medical when rated by MarketBeat users. However, 85.71% of users gave Journey Medical an outperform vote while only 64.02% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16964.02% Underperform Votes9535.98% Journey MedicalOutperform Votes685.71% Underperform Votes114.29% Do insiders and institutionals hold more shares of REPL or DERM? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 13.2% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to REPL or DERM? In the previous week, Replimune Group had 7 more articles in the media than Journey Medical. MarketBeat recorded 9 mentions for Replimune Group and 2 mentions for Journey Medical. Replimune Group's average media sentiment score of 1.09 beat Journey Medical's score of 0.63 indicating that Replimune Group is being referred to more favorably in the media. Company Overall Sentiment Replimune Group Positive Journey Medical Positive Is REPL or DERM more profitable? Replimune Group has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. Replimune Group's return on equity of -54.84% beat Journey Medical's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -54.84% -42.97% Journey Medical -31.74%-132.10%-26.90% SummaryReplimune Group beats Journey Medical on 10 of the 17 factors compared between the two stocks. Remove Ads Get Journey Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DERM vs. The Competition Export to ExcelMetricJourney MedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.78M$6.33B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-6.576.8221.8317.81Price / Sales2.54225.92379.4694.58Price / Cash28.3765.6738.1534.64Price / Book5.895.866.454.00Net Income-$3.85M$141.86M$3.20B$247.23M7 Day Performance1.31%9.22%6.60%7.26%1 Month Performance17.71%-12.42%-8.50%-6.26%1 Year Performance53.73%-11.93%10.33%-0.18% Journey Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DERMJourney Medical2.3943 of 5 stars$6.18-0.5%$9.88+59.8%+40.5%$142.78M$56.13M-6.5790Short Interest ↑Positive NewsGap UpREPLReplimune Group3.5934 of 5 stars$7.49+0.4%$19.43+159.4%+5.2%$576.84MN/A-2.44210News CoverageGap DownABUSArbutus Biopharma1.7516 of 5 stars$3.01-6.8%$5.50+82.7%+12.7%$576.36M$6.17M-7.0090Gap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030News CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals4.1787 of 5 stars$11.50+7.4%$24.83+115.9%+0.5%$571.73MN/A-3.16100High Trading VolumeAVBPArriVent BioPharma1.1326 of 5 stars$16.61+1.2%$39.00+134.8%+8.9%$565.01MN/A-6.4640News CoveragePositive NewsGap DownTRVITrevi Therapeutics3.3885 of 5 stars$5.78-4.5%$17.56+203.8%+103.8%$558.82MN/A-13.1420RCKTRocket Pharmaceuticals4.6274 of 5 stars$5.19+1.4%$43.00+728.5%-75.6%$553.41MN/A-1.89240Insider TradeNews CoverageGap UpHigh Trading VolumePHARPharming Group2.4531 of 5 stars$8.11+5.5%$30.00+269.9%-24.0%$551.73M$297.20M-31.19280Short Interest ↓Positive NewsANABAnaptysBio2.5464 of 5 stars$17.78-3.9%$35.11+97.5%-21.4%$545.26M$91.28M-2.92100Positive NewsLENZLENZ Therapeutics1.7511 of 5 stars$19.50-7.9%$41.67+113.7%+6.2%$537.09MN/A-4.09110Analyst ForecastNews CoverageGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Replimune Group Competitors Arbutus Biopharma Competitors VectivBio Competitors KalVista Pharmaceuticals Competitors ArriVent BioPharma Competitors Trevi Therapeutics Competitors Rocket Pharmaceuticals Competitors Pharming Group Competitors AnaptysBio Competitors LENZ Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DERM) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Journey Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DERM Stock Free DERM Stock Alerts